Listen as Marlyn J. Mayo, MD, discusses exciting new data from AASLD 2023 for people with PBC, including a late-breaking study of a dual PPAR agonist, biochemical response rates in people treated with an FXR agonist with or without a fibrate as second-line therapy, and evaluation of hyperlipidemia, atherosclerosis, and hepatic steatosis in people with PBC.
During the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.
In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including:
Presenter:
Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas
Link to commentary:
https://bit.ly/47PmGdc
Link to reviews of other PBC studies from AASLD 2023:
https://bit.ly/3RvXXEI